Literature DB >> 2577284

Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

J N Lessem1, B N Singh.   

Abstract

Calcium-channel antagonists and beta-adrenergic blocking agents have become important modalities in the cardiovascular therapeutic armamentarium. These drugs are often administered as monotherapy to a wide range of cardiological patients with angina pectoris, hypertension, arrhythmias, congestive heart failure, and other diseases. Since within each class these drugs exhibit pharmacologic differences, it follows that their effectiveness varies in different disease states and that they exhibit a wide variety of side effects. In an attempt to optimize therapy, the individual drugs from these two classes can be combined; and the efficaciousness and side-effect profile of various combinations between calcium-channel antagonists and beta blockers are discussed in this review. Recommendations as to which patients may benefit from a combination and as to which patients may be harmed by the combination therapy will be made. Very few studies have compared the safety and efficacy of a single agent with the combination and with placebo in a controlled randomized fashion. To determine which therapy is superior and to determine which combination one should recommend under what circumstances, such placebo-controlled, randomized trials are a necessity, and will hopefully be performed although the complexity is enormous.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577284     DOI: 10.1007/bf01858108

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  143 in total

1.  The effect of verapamil on ischaemia-induced changes to the sarcolemma.

Authors:  M J Daly; J S Elz; W G Nayler
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

2.  Prevention of transcoronary macromolecular leakage after ischemia-reperfusion by the calcium entry blocker nisoldipine. Direct observations in isolated rat hearts.

Authors:  P F McDonagh; D J Roberts
Journal:  Circ Res       Date:  1986-01       Impact factor: 17.367

3.  Management of unstable angina pectoris with maximal medical treatment (combination of intravenous nitrates, beta-blockers, calcium antagonists and heparin).

Authors:  F A Thieuleux; D Vilarem; J M Lablanche; P A Asseman; C Thery; M E Bertrand
Journal:  Bibl Cardiol       Date:  1985

4.  Reduction of infarct size by early use of oral propranolol and verapamil in acute myocardial infarction.

Authors:  R C Gupta; S K Sharma; Y K Arora; K Tripathi
Journal:  J Assoc Physicians India       Date:  1985-09

5.  Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs.

Authors:  S R Hamann; K E Kaltenborn; M Vore; T G Tan; R G McAllister
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

6.  Verapamil in the treatment of hypertension.

Authors:  S N Anavekar; N Christophidis; W J Louis; A E Doyle
Journal:  J Cardiovasc Pharmacol       Date:  1981 Mar-Apr       Impact factor: 3.105

7.  Effects of nifedipine, acebutolol, and their association on exercise tolerance in patients with effort angina.

Authors:  C De Ponti; A M De Biase; S Pirelli; G Cataldo; P Salvadé; M Lanocita; B Carù
Journal:  Cardiology       Date:  1981       Impact factor: 1.869

8.  Antihypertensive effects at rest and during exercise of a calcium blocker, nifedipine, alone and in combination with metoprolol.

Authors:  L G Ekelund; C Ekelund; S Rössner
Journal:  Acta Med Scand       Date:  1982

9.  Hemodynamic effects of verapamil in the beta-blocked dog.

Authors:  T J Iberti; B Weiner; J S Stein; G Premus; E Benjamin
Journal:  Crit Care Med       Date:  1985-02       Impact factor: 7.598

10.  Haemodynamic analysis of the effects of nicardipine and metoprolol alone and in combination in coronary artery disease.

Authors:  B Silke; S P Verma; M A Frais; G Reynolds; N Jackson; S H Taylor
Journal:  Eur Heart J       Date:  1985-11       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.